coronavirus Archives -

Market Access/ News/ News/ News/ Patients

NICE rejects five COVID drugs and backs three on price, efficacy data

Phil Taylor coronavirus, COVID-19, Evusheld, HEOR, Lagevrio, NHS, NICE, Olumiant, Paxlovid, Ronapreve, Veklury, xevudy 0 Comment

NICE has recommended that three COVID-19 therapies can continue to be used to treat patients – Pfizer’s Paxlovid,

NICE rejects five COVID drugs and backs three on price, efficacy data

https://pharmaphorum.com/news/nice-rejects-five-covid-drugs-and-backs-three-on-price-efficacy-data/

Market Access/ News/ News/ News/ Sales and Marketing

Sanofi, GSK claim their first COVID jab approval

Phil Taylor coronavirus, COVID-19, COVID-19 vaccine, GlaxoSmithKline, Sanofi, vaccine, VidPrevtyn Beta 0 Comment

For all their long history in vaccines, GSK and Sanofi have struggled to get a shot for COVID-19

Sanofi, GSK claim their first COVID jab approval

https://pharmaphorum.com/news/sanofi-gsk-claim-their-first-covid-jab-approval/

Market Access/ News/ News

US clears Omicron shots from Pfizer, Moderna for children

Phil Taylor BioNTech, coronavirus, COVID-19, COVID-19 vaccine, Moderna, Omicron, paediatric, Pfizer, regulatory 0 Comment

The US authorities have authorised use of two bivalent COVID-19 booster vaccines from Pfizer/BioNTech and Moderna – targeting

US clears Omicron shots from Pfizer, Moderna for children

https://pharmaphorum.com/news/us-clears-omicron-shots-from-pfizer-moderna-for-children/

Coronavirus pharma news roundup 27/03/2020

News/ News/ R&D

AstraZeneca’s intranasal COVID vaccine fails first clinical test

Phil Taylor AstraZeneca, coronavirus, COVID-19, COVID-19 vaccine, drug delivery, intranasal, Vaxzevria 0 Comment

An intranasal formulation of AstraZeneca’s widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from

AstraZeneca’s intranasal COVID vaccine fails first clinical test

https://pharmaphorum.com/news/astrazenecas-intranasal-covid-vaccine-fails-first-clinical-test/

News/ News/ R&D

Merck’s Lagevrio ‘no better than placebo’ in COVID hospitalisations

Phil Taylor antiviral, coronavirus, COVID-19, Lagevrio, Merck & Co 0 Comment

A UK study has found that Merck & Co’s oral COVID-19 therapy Lagevrio was unable to reduce hospitalisations

Merck’s Lagevrio ‘no better than placebo’ in COVID hospitalisations

https://pharmaphorum.com/news/mercks-lagevrio-no-better-than-placebo-on-covid-hospitalisations/

Market Access/ News/ News

Pfizer’s Omicron BA.4/BA.5 vaccine recommended by CHMP

Phil Taylor BioNTech, Comirnaty, coronavirus, COVID-19, COVID-19 vaccine, EU, Omicron, Pfizer 0 Comment

Pfizer and BioNTech’s COVID-19 vaccine targeting Omicron BA.4 and BA.5 has been recommended for authorisation by the EMA’s

Pfizer’s Omicron BA.4/BA.5 vaccine recommended by CHMP

https://pharmaphorum.com/news/pfizers-omicron-ba-4-ba-5-vaccine-recommended-by-chmp/

Life science leaders sign new ‘Biotech Social Pact’ for Europe

Market Access/ News/ News/ News/ Patients

EMA panel backs COVID-19 vaccines targeting Omicron BA.1

Phil Taylor BioNTech, CHMP, coronavirus, COVID-19, COVID-19 vaccine, EU, Moderna, Omicron, Pfizer 0 Comment

The EMA’s human medicines committee (CHMP) has recommended authorisation of two COVID-19 vaccines from Moderna and Pfizer/BioNTech that

EMA panel backs COVID-19 vaccines targeting Omicron BA.1

https://pharmaphorum.com/news/ema-panel-backs-covid-19-vaccines-targeting-omicron-ba-1/

Market Access/ News/ News/ News/ Sales and Marketing

FDA clears bivalent Omicron shots from Pfizer, Moderna

Phil Taylor BioNTech, coronavirus, COVID-19, COVID-19 vaccine, EUA, Moderna, Omicron, Pfizer 0 Comment

As expected, the FDA has moved quickly to grant emergency use authorisation (EUA) to two new-generation COVID-19 mRNA

FDA clears bivalent Omicron shots from Pfizer, Moderna

https://pharmaphorum.com/news/fda-clears-bivalent-omicron-shots-from-pfizer-moderna/

News/ News/ News/ Patients/ Sales and Marketing

COVID-19 money could run out in January, says US government

Phil Taylor coronavirus, COVID-19, COVID-19 vaccine, US 0 Comment

Access to free COVID-19 test kits is coming to an end in the US this week – but

COVID-19 money could run out in January, says US government

https://pharmaphorum.com/news/covid-19-money-could-run-out-in-january-says-us-government/

Trending

coronavirus

Login